Taysha Gene Therapies (TSHA) Receivables - Other (2021 - 2026)

Taysha Gene Therapies has disclosed Receivables - Other across 6 years of filings, most recently posting $2.6 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $2.6 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (changed 0.0% YoY), and the FY2025 annual result was $2.6 million, changed 0.0% from the prior year.
• Receivables - Other came in at $2.6 million for Q1 2026 at Taysha Gene Therapies, roughly flat from $2.6 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $2.6 million in Q1 2022 to a low of $2.6 million in Q1 2022.
• The 5-year median for Receivables - Other is $2.6 million (2022), against an average of $2.6 million.
• Peak annual rise in Receivables - Other reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Taysha Gene Therapies' Receivables - Other stood at $2.6 million in 2022, then changed by 0.0% to $2.6 million in 2023, then changed by 0.0% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025, then changed by 0.0% to $2.6 million in 2026.
• The last three Receivables - Other figures came in at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.